ASGCT Webinar: Maintaining Commercial Cell Therapy Products Chain of Custody

Wednesday, February 14, 2018
February 14 at 11:00 AM ET

My Meetings Meeting Documents
Schedule of meeting sessions and special events

This webinar will be on Wednesday, February 14, 2018, at 11:00 ET. The recent widespread and commercial use of immune effector cells has led to increased complexity in maintaining chain of custody. In cellular therapy's earliest days, the cell products were managed almost exclusively by the principal investigators themselves. Today, immune effector cells are managed by a team of collection facilities, commercial manufacturers, GMP-compliant laboratories, cell processing facilities, and couriers. Dr. Sarah Nikiforow of the Dana Farber Cancer Institute / Cell Manipulation Core Facility, Dr. Rayne Rouce of the Baylor College of Medicine, Stem Cell Transplant Program, Texas Children's Hospital and Houston Methodist Hospital, and Dr. Solveig Ericson, Executive Director of the CAR-T Program at Novartis Pharmaceuticals Corporation, will discuss the importance of maintaining chain of custody for these personalized cellular therapy products, particularly commercialized cell therapy products.

Registration Fees:

These fees are available through 02/14/2018
Name Price Available To
Regular $100.00   Accredited Organization
Inspector $0.00   Inspector
Inspector Trainee



As a Matter of FACT

FACT inspectors have free access to all FACT training and educational opportunities.